Prognostic role of pan-immune-inflammation value in patients with metastatic castration-resistant prostate cancer treated with androgen receptor-signaling inhibitors.

Yazgan, Sati Coskun; Yekedüz, Emre; Utkan, Güngör; Ürün, Yüksel

Yazgan, Sati Coskun; Yekedüz, Emre; Utkan, Güngör; Ürün, Yüksel.

Afiliación

Yazgan SC; Department of Internal Medicine, Faculty of Medicine, Ankara University, Ankara, Turkey.
Yekedüz E; Department of Medical Oncology, Faculty of Medicine, Ankara University, Ankara, Turkey.
Utkan G; Cancer Research Institute, Ankara University, Ankara, Turkey.
Ürün Y; Department of Medical Oncology, Faculty of Medicine, Ankara University, Ankara, Turkey.

Prostate ; 82(15): 1456-1461, 2022 11.

Article en En | MEDLINE | ID: mdl-35899494

Asunto(s)

Acetato de Abiraterona; Neoplasias de la Próstata Resistentes a la Castración; Acetato de Abiraterona/uso terapéutico; Benzamidas; Biomarcadores; Humanos; Inflamación; Lactato Deshidrogenasas; Masculino; Nitrilos; Feniltiohidantoína; Pronóstico; Receptores Androgénicos

Palabras clave

abiraterone acetate; androgen receptor-signaling inhibitors; enzalutamide; metastatic castration-resistant prostate cancer; pan-immune inflammation value

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias de la Próstata Resistentes a la Castración / Acetato de Abiraterona Tipo de estudio: Prognostic_studies Límite: Humans / Male Idioma: En Revista: Prostate Año: 2022 Tipo del documento: Article País de afiliación: Turquía

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google